These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28140772)

  • 1. Dose Uniformity of Topical Corticosteroids: A Simulated Trial of Fluorometholone Acetate 0.1% and Loteprednol Etabonate Gel 0.5.
    Stevens CE; Bennion JL; Caldwell MC; Townley JR; Apsey DA; Schwertner HA
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):111-114. PubMed ID: 28140772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%).
    Marlowe ZT; Davio SR
    Clin Ophthalmol; 2014; 8():23-9. PubMed ID: 24357925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1.
    Marlowe ZT; Cavet ME; Coffey MJ
    Ophthalmol Ther; 2022 Feb; 11(1):435-441. PubMed ID: 34919207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.
    Yoo YJ; Yang HK; Hwang JM
    J Ocul Pharmacol Ther; 2018; 34(6):468-476. PubMed ID: 29958057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.
    Cavet ME; Glogowski S; Lowe ER; Phillips E
    J Ocul Pharmacol Ther; 2019 Jun; 35(5):291-300. PubMed ID: 30907685
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.
    Oner V; Türkcü FM; Taş M; Alakuş MF; Işcan Y
    Jpn J Ophthalmol; 2012 Jul; 56(4):312-8. PubMed ID: 22622345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%.
    Stringer W; Bryant R
    Clin Ophthalmol; 2010 Oct; 4():1119-24. PubMed ID: 20957058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO; Feng MT; Scanameo A; Price FW
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper.
    Mifflin MD; Betts BS; Frederick PA; Feuerman JM; Fenzl CR; Moshirfar M; Zaugg B
    Clin Ophthalmol; 2017; 11():1113-1118. PubMed ID: 28652697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol 0.25% (Eysuvis) for dry eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1624):75-77. PubMed ID: 33976092
    [No Abstract]   [Full Text] [Related]  

  • 19. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain.
    Salinger CL; Gaynes BI; Rajpal RK
    Am J Manag Care; 2019 Jul; 25(12 Suppl):S215-S226. PubMed ID: 31419092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
    Patel N; Nakrani H; Raval M; Sheth N
    Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.